Cure8 research brief
PANoptosis is a recently described inflammatory cell-death program that may drive intestinal barrier damage and inflammation in IBD.
Understanding whether commonly studied traditional Chinese medicine compounds can modulate PANoptosis could point to new therapeutic strategies, but current evidence is largely preclinical and indirect.
Researchers studying IBD pathogenesis, immunologists focused on cell-death pathways, clinicians interested in mechanistic research and novel therapeutic targets, and patients curious about preclinical research on complementary medicines.
This review summarizes emerging evidence that PANoptosis — an integrated program combining features of pyroptosis, apoptosis, and necroptosis — may contribute to intestinal injury and inflammation in IBD, and examines how traditional Chinese medicine (TCM) compounds might modulate PANoptosis-related sensors, adaptors, and effectors.
The authors note that some compounds (for example, baicalin) have mechanistic data in immune cells implicating interference with ZBP1-PANoptosome assembly, but direct evidence in intestinal epithelial models or human IBD tissues is limited.
The article highlights gaps: many proposed mechanisms are extrapolated from non-intestinal models or from separate cell-death pathways rather than validated PANoptosis assays in intestinal epithelial cells, organoids, standard colitis models (DSS/TNBS/IL-10-deficient), or patient samples.
The review therefore calls for targeted in vitro and in vivo experiments to confirm whether TCM agents truly inhibit PANoptosis in the gut. If you are reading this as a patient or caregiver, note that this is a mechanistic, preclinical-focused review and does not provide evidence that TCM treatments are proven effective or safe for IBD in humans.
It is useful for understanding potential future research directions rather than current treatment recommendations.
This article is a narrative review (abstract-level extraction provided). The mechanistic links between TCM compounds and PANoptosis are often inferred from non-intestinal or immune-cell studies; direct data in intestinal epithelial models, organoids, standard animal colitis models, or human IBD tissue are limited and needed before translational conclusions can be drawn.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...
The microbiome is increasingly viewed as an influence on IBD development and persistence, and microbiome-directed therapies (like FMT and engineered bacteria) are an active area of research that could one day add to...
This review describes a novel, targeted microbiome approach (phage therapy) aimed at bacteria linked to Crohn’s disease. If effective and proven safe in trials, phage therapy could offer a more precise way to reduce...
